Article ID Journal Published Year Pages File Type
5618913 Nutrition, Metabolism and Cardiovascular Diseases 2017 29 Pages PDF
Abstract
Dapagliflozin, when added in real life to patients with T2DM treated with GLP1-RAs, induced a further significant, albeit modest improvement in A1C and a further weight loss.
Keywords
Related Topics
Health Sciences Medicine and Dentistry Cardiology and Cardiovascular Medicine
Preview
Real-world effectiveness and safety of dapagliflozin therapy added to a GLP1 receptor agonist in patients with type 2 diabetes
Authors
, , , , ,